Press Releases May 13, 2026 04:15 PM

Axis Capital Declares Quarterly Dividends

AXIS Capital Announces Quarterly Dividends for Common and Preferred Shares

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
AXS

AXIS Capital Holdings Limited declared a quarterly dividend of $0.44 per common share and $34.375 per Series E 5.50% preferred share, payable July 15, 2026, reflecting the company's strong financial position and commitment to shareholder returns.

Axis Capital Declares Quarterly Dividends
AXS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Quarterly dividend of $0.44 declared for common shares, payable July 15, 2026.
  • Dividend of $34.375 declared for Series E 5.50% preferred shares, payable July 15, 2026.
  • AXIS Capital maintains strong financial strength ratings from Standard & Poor's (A+) and A.M. Best (A).

PEMBROKE, Bermuda, May 13, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited ("AXIS Capital" or the “Company”) (NYSE: AXS) today announced that its Board of Directors has declared a quarterly dividend of $0.44 per common share payable on July 15, 2026 to shareholders of record at the close of business on June 30, 2026.

In addition, the Board declared a dividend of $34.375 per Series E 5.50% preferred share (equivalent to $0.34375 per depositary share) payable on July 15, 2026 to shareholders of record at the close of business on June 30, 2026.

About AXIS Capital
AXIS Capital, through its operating subsidiaries, is a global specialty underwriter and provider of insurance and reinsurance solutions. The Company has shareholders' equity of $6.4 billion at March 31, 2026, and locations in Bermuda, the United States, Europe, Singapore and Canada. Its operating subsidiaries have been assigned a financial strength rating of "A+" ("Strong") by Standard & Poor's and "A" ("Excellent") by A.M. Best. For more information about AXIS Capital, visit our website at www.axiscapital.com.

Follow AXIS Capital on LinkedIn and X Corp.

Investor ContactMedia ContactCliff Gallant
Nichola Liboro+1 (415) 262-6843+1 (212) 940-3394investorrelations@axiscapital.comnichola.liboro@axiscapital.com

Risks

  • Potential fluctuations in underwriting and reinsurance markets impacting AXIS Capital's earnings and dividend sustainability.
  • Dependence on global economic conditions influencing insurance and reinsurance demand.
  • Exposure to regulatory changes in multiple jurisdictions where the company operates, including Bermuda, the U.S., Europe, Singapore, and Canada.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026